Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases.
Pozelimab binds with human C5 and cynomolgus monkey C5 with Kd values of 262 pM and 8.55 nM, respectively at 37˚C, pH7.4[1].Pozelimab blocks classic pathway (CP)-mediated hemolysis in normal human and cynomolgus monkey serum with IC50 values of 2.8 and 20 nM, respectively at 37˚C, pH7.4[1].Pozelimab blocks alternative pathway (AP)-mediated hemolysis in normal human and cynomolgus monkey serum with IC50 values of 26 and 8.9 nM, respectively at 37˚C, pH7.4[1].Pozelimab binds to human C5, cynomolgus monkey C5, human R885C C5 and human C5b,6 with Kd values of 0.189, 2.73, 0.422, 0.465 and 0.137 nM respectively at 25˚C, pH7.4[1].
Pozelimab (15 mg/kg; s.c., once) has a prolonged pharmacokinetic (PK) with a half-life of approximately 13 days in male and female C5hu/hu mice[1].
References:
[1]. Latuszek A, et al. Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5. PLoS One. 2020 May 8;15(5):e0231892.